臨床試験

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT: NCT06831136 · RECRUITING

NCT識別子NCT06831136

ステータスRECRUITING

開始日2025-03-26

完了2030-01-20

SponsorThe University of Texas Health Science Center, Houston (OTHER)

First posted2025-02-17

Last updated2026-10-08

概要

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。